Post hoc clinical effectiveness analyses
The CARAT questionnaire is a validated useful tool for facilitating optimal control of both asthma and allergic rhinitis simultaneouslyand is described in a recent EAACI position paper and included in Dutch guidelines. CARAT scores vary from 0 points (worst) to 30 points (best) outcome. The minimal clinical important difference (MCID) for CARAT scores was established at a 4 points difference in 2015. Changes equal or more than MCID, with a P <0.05 for difference in means, were considered indicative for clinical effectiveness.